Business Context and Reporting Period
This Form 8-K was filed by pSivida Corp. on November 2, 2016. The filing reports the appointment of Deb Jorn as Executive Vice President (EVP), Corporate and Commercial Development, effective November 2, 2016.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms:
- Base Salary: $380,000 per year.
- Target Annual Bonus: 40% of base salary.
- Equity Awards:
- Option to purchase 300,000 shares of common stock (25% vesting annually over four years).
- Restricted stock units (RSUs) for up to 200,000 shares contingent on total shareholder return targets measured on the third anniversary.
Material Changes
The primary material change is the addition of Deb Jorn to the executive leadership team. Ms. Jorn brings over 30 years of experience in global pharmaceutical business strategy, including prior roles as EVP at Valeant Pharmaceuticals International and Chief Global Marketing Officer at Bausch & Lomb.
Outlook, Risks, and Unusual Items
Management Commentary: The appointment is intended to leverage Ms. Jorn's expertise in building global pharmaceutical businesses and designing marketing strategies across therapeutic areas.
Compensatory Arrangements and Risks:
- Termination Provisions: In the event of termination without "Cause" or resignation for "Good Cause," Ms. Jorn is eligible for up to 12 months of base salary continuation, a pro-rated target bonus, and COBRA premium payments.
- Change of Control: The agreement includes full vesting of assumed options and RSUs, as well as extended exercise periods, upon a qualifying Change of Control followed by termination without "Cause" or for "Good Cause."
Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the full text of the Employment Agreement filed as an exhibit to the Form 10-Q for the quarter ended September 30, 2016.
- Confirm the specific performance goals established by the Board of Directors for the annual cash bonus.
- Review the definitions of "Cause," "Good Cause," and "Change of Control" within the Employment Agreement to understand termination triggers.
- Monitor the press release (Exhibit 99.1) for additional strategic context regarding the appointment.